Bevenopran Explained

Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation.[1] [2] [3] It reached phase III clinical trials for this indication before being discontinued.[4] [5]

See also

Notes and References

  1. Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF . Novel opioid antagonists for opioid-induced bowel dysfunction . Expert Opin Investig Drugs . 20 . 8 . 1047–56 . 2011 . 21663526 . 10.1517/13543784.2011.592830 . 207475985 .
  2. Siemens W, Gaertner J, Becker G . Advances in pharmacotherapy for opioid-induced constipation - a systematic review . Expert Opin Pharmacother . 16 . 4 . 515–32 . 2015 . 25539282 . 10.1517/14656566.2015.995625 . 34614812 .
  3. Book: Annual Reports in Medicinal Chemistry. 13 September 2013. Elsevier Science. 978-0-12-417151-0. 451–.
  4. http://paindr.com/wp-content/uploads/2014/12/OICPAMORA.pdf Combating Opioid-Induced Constipation: New and Emerging Therapies
  5. http://adisinsight.springer.com/drugs/800030930 Bevenopran

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bevenopran".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.